US small/mid-cap pharma outlook: top picks from a 15-stock screen

Investing.com reports on a US small/mid-cap pharma outlook, highlighting a 15-stock screen. The sector is driven by strong stock momentum rather than sector-wide growth. Fifteen US pharma companies with market caps between $300M and $10B were considered, and 15 were identified. Harmony Biosciences (HRMY) emerges as the top pick, boasting an 'Excellent' health label, a 24.3% revenue growth rate, a 7.4x forward P/E ratio, and an analyst upside of 20.8%.

Despite its 3-month return of 6.4%, it has not grown as rapidly as competitors like Eton (ETON), which has a 47.6% return. HRMY's concentrated product exposure and upcoming patent expiration are factors to consider, but the data-driven selection is not a buy recommendation. Indivior (INDV) follows as the runner-up on valuation. This summary was generated with AI assistance and reviewed by an editor.